Literature DB >> 2199202

The effects of ingestion time of gliclazide in relationship to meals on plasma glucose, insulin and C-peptide levels.

J Batch1, A Ma, D Bird, R Noble, B Charles, P Ravenscroft, D Cameron.   

Abstract

The effect of altering the timing of gliclazide administration in relation to a meal was studied in ten type 2 (non-insulin dependent) chronically treated diabetics. Gliclazide was given 30 min before, at the start of and 30 min after breakfast or omitted altogether. Plasma gliclazide was present at greater than 2 mg/l throughout the study periods. Administration at 30 min after the meal significantly delayed the time to peak for plasma gliclazide. No significant difference was noted in plasma glucose, insulin or c-peptide patterns with any protocol. It is concluded that, in clinical practice, with chronically treated diabetics the timing of gliclazide ingestion in relation to meals is not critical.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2199202     DOI: 10.1007/bf02336685

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patients.

Authors:  G Sartor; B Scherstén; A Melander
Journal:  Acta Med Scand       Date:  1978

2.  The effect of food on the bioavailability and pharmacodynamics of tolbutamide in diabetic patients.

Authors:  E J Antal; W R Gillespie; J P Phillips; K S Albert
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Improved effect of glibenclamide on administration before breakfast.

Authors:  G Sartor; I Lundquist; A Melander; B Scherstén; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide.

Authors:  G Sartor; A Melander; B Scherstén; E Wåhlin-Boll
Journal:  Diabetologia       Date:  1980-01       Impact factor: 10.122

5.  Influence of food intake on the absorption and effect of glipizide in diabetics and in healthy subjects.

Authors:  E Wåhlin-Boll; A Melander; G Sartor; B Scherstén
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

6.  Influence of food and age on the single-dose kinetics and effects of tolbutamide and chlorpropamide.

Authors:  G Sartor; A Melander; B Scherstén; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

7.  Observations on comparisons of within-run and day-to-day precision.

Authors:  J S Krouwer
Journal:  Clin Chem       Date:  1981-01       Impact factor: 8.327

8.  The effects of long term gliclazide administration on insulin secretion and insulin sensitivity.

Authors:  A Ma; M Kamp; D Bird; V Howlett; D P Cameron
Journal:  Aust N Z J Med       Date:  1989-02

9.  Measurement of gliclazide in plasma by radial compression reversed-phase liquid chromatography.

Authors:  B G Charles; P J Ravenscroft
Journal:  Clin Chem       Date:  1984-11       Impact factor: 8.327

10.  Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects.

Authors:  G Ward; L C Harrison; J Proietto; P Aitken; A Nankervis
Journal:  Diabetes       Date:  1985-03       Impact factor: 9.461

View more
  3 in total

1.  Effect of magnesium hydroxide on the absorption and efficacy of tolbutamide and chlorpropamide.

Authors:  K T Kivistö; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.

Authors:  K J Palmer; R N Brogden
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

3.  Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.

Authors:  T M Davis; F Daly; J P Walsh; K F Ilett; J P Beilby; L J Dusci; P H Barrett
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.